Search Results

Clinical Trial: Car-T Cell Therapy for Prostate Cancer | Mark Moyad, MD, MPH & Mark Scholz, MD

Clinical Trial: Car-T Cell Therapy for Prostate Cancer | Mark Moyad, MD, MPH & Mark Scholz, MD

Immunotherapy in 2022: Provenge, Keytruda, Car-T, and Leukine for Prostate Cancer | Mark Scholz, MD

Immunotherapy in 2022: Provenge, Keytruda, Car-T, and Leukine for Prostate Cancer | Mark Scholz, MD

Taking Testosterone During Intermittent Hormone Therapy | Mark Moyad, MD, MPH & Mark Scholz, MD

Taking Testosterone During Intermittent Hormone Therapy | Mark Moyad, MD, MPH & Mark Scholz, MD

Remission and Cure After Relapse Prostate Cancer | Mark Scholz, MD | PCRI

Remission and Cure After Relapse Prostate Cancer | Mark Scholz, MD | PCRI

Does Hormone Therapy Cause Cognitive Decline? | Answering YouTube Comments #62 | Mark Scholz, MD

Does Hormone Therapy Cause Cognitive Decline? | Answering YouTube Comments #62 | Mark Scholz, MD

PSMA targeted CAR-T therapy for prostate cancer

PSMA targeted CAR-T therapy for prostate cancer

Small Cell Tumors and Prostate Cancer | Answering YouTube Comments #29 | Mark Scholz, MD

Small Cell Tumors and Prostate Cancer | Answering YouTube Comments #29 | Mark Scholz, MD

CAR-T promising new prostate cancer treatments. #shorts

CAR-T promising new prostate cancer treatments. #shorts

Dr. Tanya Dorff on New CAR T Cell Therapy for Prostate Cancer | ASCO22

Dr. Tanya Dorff on New CAR T Cell Therapy for Prostate Cancer | ASCO22

Immune, Hormone, & Radiation Combined for Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

Immune, Hormone, & Radiation Combined for Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

CAR T Cell Therapy: How It Works

CAR T Cell Therapy: How It Works

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI